Literature DB >> 31274600

Epidural Analgesia During Childbirth and Postpartum Depressive Symptoms: A Population-Based Longitudinal Cohort Study.

Patricia Eckerdal1, Natasa Kollia2, Linnea Karlsson3, Agneta Skoog-Svanberg1, Anna-Karin Wikström1, Ulf Högberg1, Alkistis Skalkidou1.   

Abstract

BACKGROUND: Severe pain has been linked to depression, which raises the question of whether epidural analgesia (EDA) during childbirth is associated with a reduced risk of postpartum depression (PPD). This association has been explored previously, but the studies were restricted by small sample sizes and the inability to control for relevant confounders. This study aimed to investigate the association between the administration of EDA and the development of PPD after adjusting for sociodemographic, psychosocial, and obstetric variables.
METHODS: Data were retrieved from the Biology, Affect, Stress, Imaging and Cognition (BASIC) project (2009-2017), a population-based longitudinal cohort study of pregnant women conducted at Uppsala University Hospital, Sweden. The outcome was PPD at 6 weeks postpartum, defined as a score of ≥12 points on the Edinburgh Postnatal Depression Scale (EPDS). Information was collected through medical records and self-reported web-based questionnaires during pregnancy and 6 weeks after childbirth. Only primiparous women with spontaneous start of childbirth were included (n = 1503). The association between EDA and PPD was examined in multivariable logistic regression models, adjusting for sociodemographic, psychosocial, and obstetric variables. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs).
RESULTS: Of the 1503 women included in the analysis, 800 (53%) reported use of EDA during childbirth. PPD at 6 weeks postpartum was present in 193 (13%) women. EDA was not associated with higher odds of PPD at 6 weeks postpartum after adjusting for suspected confounders (age, fear of childbirth, antenatal depressive symptoms; adjusted OR [aOR] = 1.22; 95% CI, 0.87-1.72).
CONCLUSIONS: EDA was not associated with the risk of PPD at 6 weeks postpartum after adjusting for sociodemographic, psychosocial, and obstetric variables. However, these findings do not preclude a potential association between PPD and childbirth pain or other aspects of EDA that were not assessed in this study.

Entities:  

Year:  2020        PMID: 31274600     DOI: 10.1213/ANE.0000000000004292

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Labor Pain, Analgesia, and Postpartum Depression: Are We Asking the Right Questions?

Authors:  Grace Lim; Michele D Levine; Edward J Mascha; Ajay D Wasan
Journal:  Anesth Analg       Date:  2020-03       Impact factor: 5.108

2.  Perinatal depression.

Authors:  Sarah J Kroh; Grace Lim
Journal:  Int Anesthesiol Clin       Date:  2021-07-01

3.  Predictors of Postpartum Depression among Italian Women: A Longitudinal Study.

Authors:  Sara Molgora; Emanuela Saita; Maurizio Barbieri Carones; Enrico Ferrazzi; Federica Facchin
Journal:  Int J Environ Res Public Health       Date:  2022-01-29       Impact factor: 3.390

4.  A Study on the Preventive Effect of Esketamine on Postpartum Depression (PPD) after Cesarean Section.

Authors:  Qiwei Wang; Maoxin Xiao; Hao Sun; Pengcheng Zhang
Journal:  Comput Math Methods Med       Date:  2022-08-08       Impact factor: 2.809

Review 5.  Childbirth Pain, Labor Epidural Analgesia, and Postpartum Depression: Recent Evidence and Future Directions.

Authors:  Weijia Du; Lulong Bo; Zhendong Xu; Zhiqiang Liu
Journal:  J Pain Res       Date:  2022-09-24       Impact factor: 2.832

Review 6.  Perinatal depression.

Authors:  Grace Lim
Journal:  Curr Opin Anaesthesiol       Date:  2021-06-01       Impact factor: 2.733

7.  The association between labor epidural analgesia and postpartum depression: a systematic review and meta-analysis.

Authors:  Marcela Almeida; Katherine A Kosman; Mark C Kendall; Gildasio S De Oliveira
Journal:  BMC Womens Health       Date:  2020-05-11       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.